ACER
Acer Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-09-2018 | 08-13-2018 | 05-14-2018 | 03-07-2018 | 11-13-2017 | 08-14-2017 | 05-12-2017 | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.43 | -0.64 | -0.53 | -0.63 | -1.09 | -0.93 | -1.24 |
| Consensus EPS | -0.53 | -0.54 | -0.69 | -0.56 | |||
| Estimated EPS | -0.53 | -0.54 | -0.69 | -0.56 | |||
| Number of Estimates | 5 | 5 | 3 | 2 | |||
| EPS Surprise | $0.10 | -$0.10 | $0.16 | -$0.07 |
Stats
Summary
Acer Therapeutics Inc is a pharmaceutical company that acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need.
Market Cap: 143 Million
Primary Exchange: NASDAQ Capital Market
Website: https://www.acertx.com
Shares Outstanding: 7.5 Million
Float: 2.05 Million
Dividend: 0.0 (0.0%)
Beta: 2.519044
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 43.9 Thousand
Ethical Flags
Longest drawdown: 1520 trading days
From: 2013-02-05 To: 2019-02-21
Lowest Point:
Acer Therapeutics: Multiple Aces Up Its Sleeve
via: SeekingAlpha at 2019-02-11 20:16:54:000
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on … read more...
Acer Therapeutics: Multiple Aces Up Its Sleeve
via: SeekingAlpha at 2019-02-11 20:16:54:000
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on … read more...
Acer Therapeutics: Multiple Aces Up Its Sleeve
via: SeekingAlpha at 2019-02-11 20:16:54:000
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on … read more...
FDA accepts Acer Therapeutics' NDA and priority review for EDSIVO for the treatment of vEDS
via: SeekingAlpha at 2018-12-26 08:52:17:000
Acer Therapeutics (NASDAQ: ACER ) announces that the FDA has accepted for review Acers NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. More news on: Acer Therapeutics Inc., Healthcare sto… read more...
FDA accepts Acer Therapeutics' NDA and priority review for EDSIVO for the treatment of vEDS
via: SeekingAlpha at 2018-12-26 08:52:17:000
Acer Therapeutics (NASDAQ: ACER ) announces that the FDA has accepted for review Acers NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. More news on: Acer Therapeutics Inc., Healthcare sto… read more...
FDA accepts Acer Therapeutics' NDA and priority review for EDSIVO for the treatment of vEDS
via: SeekingAlpha at 2018-12-26 08:52:17:000
Acer Therapeutics (NASDAQ: ACER ) announces that the FDA has accepted for review Acers NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. More news on: Acer Therapeutics Inc., Healthcare sto… read more...
Acer Therapeutics: Celiprolol Is Promising, But Acer Could Have Done A Proper Trial
via: SeekingAlpha at 2018-11-19 13:37:35:000
Acer Therapeutics ( ACER ) focuses on treating orphan diseases. Its lead drug candidate Edsivo (celiprolol) had an NDA submitted to the FDA 3 weeks ago targeting vEDS or Vascular Ehlers-Danlos Syndrome. The NDA is based on a French government-backed study of celiprolol that was published i… read more...
Acer Therapeutics: Celiprolol Is Promising, But Acer Could Have Done A Proper Trial
via: SeekingAlpha at 2018-11-19 13:37:35:000
Acer Therapeutics ( ACER ) focuses on treating orphan diseases. Its lead drug candidate Edsivo (celiprolol) had an NDA submitted to the FDA 3 weeks ago targeting vEDS or Vascular Ehlers-Danlos Syndrome. The NDA is based on a French government-backed study of celiprolol that was published i… read more...
Acer Therapeutics: Celiprolol Is Promising, But Acer Could Have Done A Proper Trial
via: SeekingAlpha at 2018-11-19 13:37:35:000
Acer Therapeutics ( ACER ) focuses on treating orphan diseases. Its lead drug candidate Edsivo (celiprolol) had an NDA submitted to the FDA 3 weeks ago targeting vEDS or Vascular Ehlers-Danlos Syndrome. The NDA is based on a French government-backed study of celiprolol that was published i… read more...
Acer Therapeutics beats by $0.04
via: SeekingAlpha at 2018-11-09 16:06:39:000
Acer Therapeutics (NASDAQ: ACER ): Q3 GAAP EPS of -$0.43 beats by $0.04 . Cash and cash equivalents of $46.2M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics beats by $0.04
via: SeekingAlpha at 2018-11-09 16:06:39:000
Acer Therapeutics (NASDAQ: ACER ): Q3 GAAP EPS of -$0.43 beats by $0.04 . Cash and cash equivalents of $46.2M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics beats by $0.04
via: SeekingAlpha at 2018-11-09 16:06:39:000
Acer Therapeutics (NASDAQ: ACER ): Q3 GAAP EPS of -$0.43 beats by $0.04 . Cash and cash equivalents of $46.2M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics beats by $0.04
via: SeekingAlpha at 2018-11-09 16:06:39:000
Acer Therapeutics (NASDAQ: ACER ): Q3 GAAP EPS of -$0.43 beats by $0.04 . Cash and cash equivalents of $46.2M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics beats by $0.04
via: SeekingAlpha at 2018-11-09 16:06:39:000
Acer Therapeutics (NASDAQ: ACER ): Q3 GAAP EPS of -$0.43 beats by $0.04 . Cash and cash equivalents of $46.2M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer files U.S. marketing application for Edsivo for connective tissue disorder
via: SeekingAlpha at 2018-10-29 09:15:15:000
Acer Therapeutics (NASDAQ: ACER ) has filed a New Drug Application (NDA) with the FDA seeking approval for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by defects in a gene that encodes collagen. The company has requ… read more...
Acer files U.S. marketing application for Edsivo for connective tissue disorder
via: SeekingAlpha at 2018-10-29 09:15:15:000
Acer Therapeutics (NASDAQ: ACER ) has filed a New Drug Application (NDA) with the FDA seeking approval for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by defects in a gene that encodes collagen. The company has requ… read more...
Acer files U.S. marketing application for Edsivo for connective tissue disorder
via: SeekingAlpha at 2018-10-29 09:15:15:000
Acer Therapeutics (NASDAQ: ACER ) has filed a New Drug Application (NDA) with the FDA seeking approval for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by defects in a gene that encodes collagen. The company has requ… read more...
Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative Business Model
via: SeekingAlpha at 2018-09-25 06:08:04:000
ACER data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately h… read more...
Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative Business Model
via: SeekingAlpha at 2018-09-25 06:08:04:000
ACER data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately h… read more...
Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative Business Model
via: SeekingAlpha at 2018-09-25 06:08:04:000
ACER data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately h… read more...
Daily Insider Ratings Round Up 8/22/18
via: SeekingAlpha at 2018-08-24 09:39:44:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 8/22/18
via: SeekingAlpha at 2018-08-24 09:39:44:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 8/22/18
via: SeekingAlpha at 2018-08-24 09:39:44:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 8/22/18
via: SeekingAlpha at 2018-08-24 09:39:44:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Daily Insider Ratings Round Up 8/22/18
via: SeekingAlpha at 2018-08-24 09:39:44:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi… read more...
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
via: SeekingAlpha at 2018-08-14 08:58:04:000
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
via: SeekingAlpha at 2018-08-14 08:58:04:000
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
via: SeekingAlpha at 2018-08-14 08:58:04:000
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...
Acer Therapeutics misses by $0.09
via: SeekingAlpha at 2018-08-13 16:19:35:000
Acer Therapeutics (NASDAQ: ACER ): Q2 EPS of -$0.64 misses by $0.09 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Acer on track for Q4 NDA for Edviso for vEDS
via: SeekingAlpha at 2018-08-13 16:09:22:000
Acer Therapeutics (NASDAQ: ACER ) Q2 results ($M): Operating expenses: 4.9 (+157.9%); net loss: (4.8) (-54.8%). More news on: Acer Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
via: SeekingAlpha at 2018-05-15 10:00:00:000
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf… read more...
Acer Therapeutics EPS of -$0.11
via: SeekingAlpha at 2018-05-14 16:28:39:000
Acer Therapeutics (NASDAQ: ACER ): Q1 EPS of -$0.11 may not be comparable to consensus of -$0.69. Cash, cash equivalents and securities available-for-sale of $22.1M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics EPS of -$0.11
via: SeekingAlpha at 2018-05-14 16:28:39:000
Acer Therapeutics (NASDAQ: ACER ): Q1 EPS of -$0.11 may not be comparable to consensus of -$0.69. Cash, cash equivalents and securities available-for-sale of $22.1M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Midday Gainers / Losers (04/13/2018)
via: SeekingAlpha at 2018-04-13 12:52:34:000
Gainers: FTFT +64% . HEAR +22% . NETE +18% . INTT +15% . ACER +15% . ISNS +14% . NCNA +13% . PLSE +12% . PXLW +12% . MYND +10% . More news on: Future Fintech Group Inc, Turtle Beach Corporation, Net Element International, Inc., Stocks on the move, , Rea… read more...
Midday Gainers / Losers (04/13/2018)
via: SeekingAlpha at 2018-04-13 12:52:34:000
Gainers: FTFT +64% . HEAR +22% . NETE +18% . INTT +15% . ACER +15% . ISNS +14% . NCNA +13% . PLSE +12% . PXLW +12% . MYND +10% . More news on: Future Fintech Group Inc, Turtle Beach Corporation, Net Element International, Inc., Stocks on the move, , Rea… read more...
Acer Therapeutics misses by $0.16
via: SeekingAlpha at 2018-03-07 16:36:42:000
Acer Therapeutics (NASDAQ: ACER ): Q4 EPS of -$0.63 misses by $0.16 . Cash and equivalents of $15.6M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics misses by $0.16
via: SeekingAlpha at 2018-03-07 16:36:42:000
Acer Therapeutics (NASDAQ: ACER ): Q4 EPS of -$0.63 misses by $0.16 . Cash and equivalents of $15.6M Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-16 07:26:51:000
Acer Therapeutics (NASDAQ: ACER ) initiated with Outperform rating with a $47 (178% upside) price target at William Blair. More news on: Acer Therapeutics Inc., Aerie Pharmaceuticals, Inc., Calithera Biosciences, Healthcare stocks news, Read more … read more...
Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial
via: SeekingAlpha at 2017-12-30 13:35:25:000
Analysis of top Seeking Alpha coverage: Intercept Today we will discuss an update from Intercept Pharmaceuticals ( ICPT ) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. Intercept had earlier guided for commencing the Phase 3 trial by the end of this year… read more...
Acer Therapeutics announces partial exercise of over-allotment option in public offering
via: SeekingAlpha at 2017-12-28 08:22:30:000
Acer Therapeutics (NASDAQ: ACER ) announces that the underwriters of its previous public offering of common stock have partially exercised their over-allotment option by purchasing an additional 130,000 shares at a price of $12 per share, resulting in additional gross proceeds of $1.56M…. read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2017-12-20 08:20:11:000
Moleculin Biotech (NASDAQ: MBRX ) initiated with Buy rating and $8 (373% upside) price target by Roth Capital. Shares up 7% premarket on light volume. More news on: Moleculin Biotech, Inc., Audentes Therapeutics, Acer Therapeutics Inc., Healthcare stocks news, Stocks on the mov… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-12-12 12:40:40:000
Gainers: PTI +161% . TIK +46% . RIOT +33% . GLYC +25% . ELTK +24% . DPW +21% . PYDS +20% . TCCO +18% . SRI +17% . BSQR +18% . More news on: Proteostasis Therapeutics, Tel-Instrument Electronics Corp, Riot Blockchain, Inc., Stocks on the move, Read more … read more...
Acer prices equity offering, shares down 12% premarket
via: SeekingAlpha at 2017-12-12 09:18:15:000
Acer Therapeutics (NASDAQ: ACER ) prices its public offering of 916,667 shares of common stock at $12 per share. Underwriters over-allotment is an additional 137.5K shares. Closing date is December 14. More news on: Acer Therapeutics Inc., Healthcare stocks news, Stocks on the move, … read more...
Acer Therapeutics beats by $0.15
via: SeekingAlpha at 2017-11-13 16:32:24:000
Acer Therapeutics (NASDAQ: ACER ): Q3 EPS of -$1.09 beats by $0.15 . Cash of $8.4M. Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Acer Therapeutics (ACER) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-09-27 14:14:05:000
The following slide deck was published by Acer Therapeutics Inc. in conjunction with this Read more … read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-07-12 12:37:17:000
Gainers: CHKE +25% . NTP +22% . NRG +20% . DAC +17% . IDSY +14% . PDFS +14% . LTEA +13% . CYRX +13% . DMTX +13% . VSTM +12% . More news on: Cherokee Inc., Nam Tai Property Inc., NRG Energy, Inc., Stocks on the move, Read more … read more...
Premarket Losers as of 9:05 am
via: SeekingAlpha at 2017-07-06 09:13:33:000
EGLT -31% on announcing public offering of common stock and warrants. More news on: Egalet Ltd., Tahoe Resources Inc., PhotoMedex, Inc., Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am
via: SeekingAlpha at 2017-07-05 09:24:05:000
MSDI +38% . More news on: Monster Digital, DryShips Inc., Celsion Corporation, Stocks on the move, Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2017-09-21 | 10.355527 | 1.0 | 10.355527 | |||
| 2015-09-29 | 8.0 | 1.0 | 8.0 |